Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BlossomHill Therapeutics, Inc.BLSM · Entity 5423 | Director · President and CEO · 10% owner | August 06, 2026 | August 10, 2026 |
| Turning Point Therapeutics, Inc.TPTX · Entity 124461 | Director | June 09, 2020 | June 10, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BlossomHill Therapeutics, Inc.
Report date August 06, 2026 · Filed August 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy The Li and Cui Family Trust | 1,714,117 |
Last balance in matching sequence
After 2026-08-10 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-08-10 · Conversion · Acquired 1,600,682 · Balance 1,600,682 F1: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of The Li and Cui Family Trust (the "Trust") and have voting and dispositive power over the securities held by the Trust. Row 2 · 2026-08-10 · Conversion · Acquired 113,435 · Balance 1,714,117 F1: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of The Li and Cui Family Trust (the "Trust") and have voting and dispositive power over the securities held by the Trust. |
| Common StockSEC Table I · non-derivative | IndirectBy RongShan, LLC | 124,779 |
Reported balance
After 2026-08-10 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-08-10 · Conversion · Acquired 124,779 · Balance 124,779 F1: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F3: The Reporting Person's spouse is the manager of RongShan, LLC. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-08-05 | Direct | 676,205 |
Reported balance
After 2026-08-06 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-06 · Grant · Acquired 676,205 · Balance 676,205 F4: 1/4th of the shares subject to the option shall vest on August 6, 2027, and the balance of the shares shall vest in equal monthly installments over the following 36 months. |
| Series Angel Preferred StockSEC Table II · derivative / convertible security | IndirectBy The Li and Cui Family Trust | 0 |
Reported balance
After 2026-08-10 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-10 · Conversion · Disposed 1,600,682 · Balance 0 F1: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of The Li and Cui Family Trust (the "Trust") and have voting and dispositive power over the securities held by the Trust. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy The Li and Cui Family Trust | 0 |
Reported balance
After 2026-08-10 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-08-10 · Conversion · Disposed 113,435 · Balance 0 F1: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of The Li and Cui Family Trust (the "Trust") and have voting and dispositive power over the securities held by the Trust. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy RongShan, LLC | 0 |
Reported balance
After 2026-08-10 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-08-10 · Conversion · Disposed 124,779 · Balance 0 F1: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F3: The Reporting Person's spouse is the manager of RongShan, LLC. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | Direct | 1,067,121 |
Reported balance
Holding disclosure · report date 2026-08-06 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,067,121 |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 1,067,121 |
Reported balance
Holding disclosure · report date 2026-08-06 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 1,067,121 |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
F2: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of The Li and Cui Family Trust (the "Trust") and have voting and dispositive power over the securities held by the Trust.
F3: The Reporting Person's spouse is the manager of RongShan, LLC. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
F4: 1/4th of the shares subject to the option shall vest on August 6, 2027, and the balance of the shares shall vest in equal monthly installments over the following 36 months.
Turning Point Therapeutics, Inc.
Report date June 09, 2020 · Filed June 10, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy spouse | 549,471 |
Reported balance
After 2020-06-09 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2020-06-09 · Sale · Disposed 412 · Balance 549,471 F1: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F2: The weighted average sale price for the transaction reported was $63.80, and the range of prices were between $63.25 and $64.20. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| Common StockSEC Table I · non-derivative | IndirectBy spouse | 547,783 |
Reported balance
After 2020-06-09 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2020-06-09 · Sale · Disposed 1,688 · Balance 547,783 F1: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F3: The weighted average sale price for the transaction reported was $64.82, and the range of prices were between $64.26 and $65.17. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| Common StockSEC Table I · non-derivative | IndirectBy spouse | 543,268 |
Reported balance
After 2020-06-09 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2020-06-09 · Sale · Disposed 4,515 · Balance 543,268 F1: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F4: The weighted average sale price for the transaction reported was $65.80, and the range of prices were between $65.26 and $66.24. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| Common StockSEC Table I · non-derivative | IndirectBy spouse | 540,683 |
Reported balance
After 2020-06-09 transaction · row 6
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 6 · 2020-06-09 · Sale · Disposed 2,585 · Balance 540,683 F1: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F5: The weighted average sale price for the transaction reported was $66.60, and the range of prices were between $66.27 and $67.18. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| Common StockSEC Table I · non-derivative | IndirectBy spouse | 540,383 |
Reported balance
After 2020-06-09 transaction · row 7
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 7 · 2020-06-09 · Sale · Disposed 300 · Balance 540,383 F1: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F6: The weighted average sale price for the transaction reported was $67.48, and the range of prices were between $67.34 and $67.915. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| Common StockSEC Table I · non-derivative | Direct | 1,001,298 |
Reported balance
Holding disclosure · report date 2020-06-09 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,001,298 |
| Common StockSEC Table I · non-derivative | IndirectBy The Jean Cui 2020 GRAT | 300,000 |
Reported balance
Holding disclosure · report date 2020-06-09 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 300,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li.
F2: The weighted average sale price for the transaction reported was $63.80, and the range of prices were between $63.25 and $64.20. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F3: The weighted average sale price for the transaction reported was $64.82, and the range of prices were between $64.26 and $65.17. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F4: The weighted average sale price for the transaction reported was $65.80, and the range of prices were between $65.26 and $66.24. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F5: The weighted average sale price for the transaction reported was $66.60, and the range of prices were between $66.27 and $67.18. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F6: The weighted average sale price for the transaction reported was $67.48, and the range of prices were between $67.34 and $67.915. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 27, 2019 Filed Feb 26, 2020 20:18 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Exercise / conversionCommon Stock | 8,080 | $3.20 | $25,856.00 |
DisclosureSEC source: 0001209191-20-013266 · doc4.xml · nonDerivative · entry 3 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 843,519 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents options exercised by Yishan (Peter) Li, who is Jean Cui's spouse. Read SEC document |
| December 20, 2019 Filed Dec 20, 2019 18:29 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 1,600 | $63.99 | $102,384.00 |
DisclosureSEC source: 0001209191-19-061640 · doc4.xml · nonDerivative · entry 12 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 936,219 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F12 · price: The weighted average sale price for the transaction reported was $63.99, and the range of prices were between $63.84 and $64.19. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 20, 2019 Filed Dec 20, 2019 18:29 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 8,500 | $63.42 | $539,070.00 |
DisclosureSEC source: 0001209191-19-061640 · doc4.xml · nonDerivative · entry 11 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 937,819 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F11 · price: The weighted average sale price for the transaction reported was $63.42, and the range of prices were between $62.95 and $63.83. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 20, 2019 Filed Dec 20, 2019 18:29 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 1,400 | $62.64 | $87,696.00 |
DisclosureSEC source: 0001209191-19-061640 · doc4.xml · nonDerivative · entry 10 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 946,319 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F10 · price: The weighted average sale price for the transaction reported was $62.64, and the range of prices were between $61.97 and $62.82. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 19, 2019 Filed Dec 20, 2019 18:29 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 2,900 | $62.33 | $180,757.00 |
DisclosureSEC source: 0001209191-19-061640 · doc4.xml · nonDerivative · entry 9 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 947,719 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F9 · price: The weighted average sale price for the transaction reported was $62.33, and the range of prices were between $62.16 and $62.44. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 19, 2019 Filed Dec 20, 2019 18:29 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 4,970 | $61.48 | $305,555.60 |
DisclosureSEC source: 0001209191-19-061640 · doc4.xml · nonDerivative · entry 8 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 950,619 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F8 · price: The weighted average sale price for the transaction reported was $61.48, and the range of prices were between $61.15 and $62.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 19, 2019 Filed Dec 20, 2019 18:29 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 9,230 | $60.69 | $560,168.70 |
DisclosureSEC source: 0001209191-19-061640 · doc4.xml · nonDerivative · entry 7 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 955,589 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F7 · price: The weighted average sale price for the transaction reported was $60.69, and the range of prices were between $60.215 and $61.11. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 19, 2019 Filed Dec 20, 2019 18:29 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 1,400 | $59.84 | $83,776.00 |
DisclosureSEC source: 0001209191-19-061640 · doc4.xml · nonDerivative · entry 6 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 964,819 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F6 · price: The weighted average sale price for the transaction reported was $59.84, and the range of prices were between $59.165 and $60.11. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 18:29 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 3,070 | $60.38 | $185,366.60 |
DisclosureSEC source: 0001209191-19-061640 · doc4.xml · nonDerivative · entry 5 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 966,219 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F5 · price: The weighted average sale price for the transaction reported was $60.38, and the range of prices were between $60.07 and $61.07. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 18:29 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 7,802 | $59.78 | $466,403.56 |
DisclosureSEC source: 0001209191-19-061640 · doc4.xml · nonDerivative · entry 4 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 969,289 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F4 · price: The weighted average sale price for the transaction reported was $59.78, and the range of prices were between $59.07 and $60.065. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 18:29 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 3,898 | $58.48 | $227,955.04 |
DisclosureSEC source: 0001209191-19-061640 · doc4.xml · nonDerivative · entry 3 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 977,091 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F3 · price: The weighted average sale price for the transaction reported was $58.48, and the range of prices were between $58.06 and $59.05. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 18:29 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 3,730 | $57.76 | $215,444.80 |
DisclosureSEC source: 0001209191-19-061640 · doc4.xml · nonDerivative · entry 2 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 980,989 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F2 · price: The weighted average sale price for the transaction reported was $57.76, and the range of prices were between $57.06 and $58.05. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 17, 2019 Filed Dec 17, 2019 21:09 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 305 | $62.71 | $19,126.55 |
DisclosureSEC source: 0001209191-19-061057 · doc4.xml · nonDerivative · entry 14 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 984,719 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F13 · price: The weighted average sale price for the transaction reported was $62.71, and the range of prices were between $62.71 and $62.74. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 17, 2019 Filed Dec 17, 2019 21:09 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 6,495 | $62.05 | $403,014.75 |
DisclosureSEC source: 0001209191-19-061057 · doc4.xml · nonDerivative · entry 13 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 985,024 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F12 · price: The weighted average sale price for the transaction reported was $62.05, and the range of prices were between $61.70 and $62.70. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 17, 2019 Filed Dec 17, 2019 21:09 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 8,100 | $61.13 | $495,153.00 |
DisclosureSEC source: 0001209191-19-061057 · doc4.xml · nonDerivative · entry 12 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 991,519 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F11 · price: The weighted average sale price for the transaction reported was $61.13, and the range of prices were between $60.68 and $61.68. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 17, 2019 Filed Dec 17, 2019 21:09 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 3,600 | $60.30 | $217,080.00 |
DisclosureSEC source: 0001209191-19-061057 · doc4.xml · nonDerivative · entry 11 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 999,619 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F10 · price: The weighted average sale price for the transaction reported was $60.30, and the range of prices were between $59.66 and $60.60. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 16, 2019 Filed Dec 17, 2019 21:09 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 200 | $60.43 | $12,086.00 |
DisclosureSEC source: 0001209191-19-061057 · doc4.xml · nonDerivative · entry 10 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,003,219 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. Read SEC document |
| December 16, 2019 Filed Dec 17, 2019 21:09 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 2,400 | $59.76 | $143,424.00 |
DisclosureSEC source: 0001209191-19-061057 · doc4.xml · nonDerivative · entry 9 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,003,419 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F9 · price: The weighted average sale price for the transaction reported was $59.76, and the range of prices were between $59.41 and $60.34. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 16, 2019 Filed Dec 17, 2019 21:09 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 5,000 | $58.75 | $293,750.00 |
DisclosureSEC source: 0001209191-19-061057 · doc4.xml · nonDerivative · entry 8 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,005,819 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F8 · price: The weighted average sale price for the transaction reported was $58.75, and the range of prices were between $58.305 and $59.265. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 16, 2019 Filed Dec 17, 2019 21:09 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 1,300 | $57.59 | $74,867.00 |
DisclosureSEC source: 0001209191-19-061057 · doc4.xml · nonDerivative · entry 7 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,010,819 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F7 · price: The weighted average sale price for the transaction reported was $57.59, and the range of prices were between $57.22 and $57.90. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 16, 2019 Filed Dec 17, 2019 21:09 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 2,000 | $56.84 | $113,680.00 |
DisclosureSEC source: 0001209191-19-061057 · doc4.xml · nonDerivative · entry 6 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,012,119 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F6 · price: The weighted average sale price for the transaction reported was $56.84, and the range of prices were between $56.20 and $57.19. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 16, 2019 Filed Dec 17, 2019 21:09 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 600 | $55.45 | $33,270.00 |
DisclosureSEC source: 0001209191-19-061057 · doc4.xml · nonDerivative · entry 5 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,014,119 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F5 · price: The weighted average sale price for the transaction reported was $55.45, and the range of prices were between $55.05 and $55.98. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 13, 2019 Filed Dec 17, 2019 21:09 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 600 | $56.95 | $34,170.00 |
DisclosureSEC source: 0001209191-19-061057 · doc4.xml · nonDerivative · entry 4 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,014,719 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F4 · price: The weighted average sale price for the transaction reported was $56.95, and the range of prices were between $56.84 and $57.04. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 13, 2019 Filed Dec 17, 2019 21:09 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 3,800 | $56.17 | $213,446.00 |
DisclosureSEC source: 0001209191-19-061057 · doc4.xml · nonDerivative · entry 3 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,015,319 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F3 · price: The weighted average sale price for the transaction reported was $56.17, and the range of prices were between $55.825 and $56.78. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 13, 2019 Filed Dec 17, 2019 21:09 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 7,100 | $55.43 | $393,553.00 |
DisclosureSEC source: 0001209191-19-061057 · doc4.xml · nonDerivative · entry 2 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,019,119 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F2 · price: The weighted average sale price for the transaction reported was $55.43, and the range of prices were between $54.775 and $55.77. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 12, 2019 Filed Dec 12, 2019 19:54 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 100 | $54.66 | $5,466.00 |
DisclosureSEC source: 0001209191-19-060295 · doc4.xml · nonDerivative · entry 9 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,026,219 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. Read SEC document |
| December 12, 2019 Filed Dec 12, 2019 19:54 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 10,900 | $54.15 | $590,235.00 |
DisclosureSEC source: 0001209191-19-060295 · doc4.xml · nonDerivative · entry 8 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,026,319 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F7 · price: The weighted average sale price for the transaction reported was $54.15, and the range of prices were between $53.64 and $54.6050. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 12, 2019 Filed Dec 12, 2019 19:54 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 500 | $53.18 | $26,590.00 |
DisclosureSEC source: 0001209191-19-060295 · doc4.xml · nonDerivative · entry 7 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,037,219 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F6 · price: The weighted average sale price for the transaction reported was $53.18, and the range of prices were between $52.63 and $53.58. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 11, 2019 Filed Dec 12, 2019 19:54 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 120 | $54.20 | $6,504.00 |
DisclosureSEC source: 0001209191-19-060295 · doc4.xml · nonDerivative · entry 6 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,037,719 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. Read SEC document |
| December 11, 2019 Filed Dec 12, 2019 19:54 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 2,452 | $53.67 | $131,598.84 |
DisclosureSEC source: 0001209191-19-060295 · doc4.xml · nonDerivative · entry 5 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,037,839 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F5 · price: The weighted average sale price for the transaction reported was $53.67, and the range of prices were between $53.19 and $54.18. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 11, 2019 Filed Dec 12, 2019 19:54 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 8,928 | $52.72 | $470,684.16 |
DisclosureSEC source: 0001209191-19-060295 · doc4.xml · nonDerivative · entry 4 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,040,291 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F4 · price: The weighted average sale price for the transaction reported was $52.72, and the range of prices were between $52.15 and $53.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 10, 2019 Filed Dec 12, 2019 19:54 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 100 | $55.51 | $5,551.00 |
DisclosureSEC source: 0001209191-19-060295 · doc4.xml · nonDerivative · entry 3 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,049,219 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. Read SEC document |
| December 10, 2019 Filed Dec 12, 2019 19:54 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 8,700 | $54.81 | $476,847.00 |
DisclosureSEC source: 0001209191-19-060295 · doc4.xml · nonDerivative · entry 2 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,049,319 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F3 · price: The weighted average sale price for the transaction reported was $54.81, and the range of prices were between $54.36 and $55.27. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 10, 2019 Filed Dec 12, 2019 19:54 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 2,700 | $53.79 | $145,233.00 |
DisclosureSEC source: 0001209191-19-060295 · doc4.xml · nonDerivative · entry 1 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,058,019 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F2 · price: The weighted average sale price for the transaction reported was $53.79, and the range of prices were between $53.34 and $54.32. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 09, 2019 Filed Dec 9, 2019 20:44 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 200 | $56.78 | $11,356.00 |
DisclosureSEC source: 0001209191-19-059779 · doc4.xml · nonDerivative · entry 10 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,060,719 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F10 · price: The weighted average sale price for the transaction reported was $56.78, and the range of prices were between $56.75 and $56.78. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 09, 2019 Filed Dec 9, 2019 20:44 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 4,200 | $55.94 | $234,948.00 |
DisclosureSEC source: 0001209191-19-059779 · doc4.xml · nonDerivative · entry 9 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,060,919 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F9 · price: The weighted average sale price for the transaction reported was $55.94, and the range of prices were between $55.74 and $56.46. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 09, 2019 Filed Dec 9, 2019 20:44 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 4,100 | $55.35 | $226,935.00 |
DisclosureSEC source: 0001209191-19-059779 · doc4.xml · nonDerivative · entry 8 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,065,119 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F8 · price: The weighted average sale price for the transaction reported was $55.35, and the range of prices were between $54.70 and $55.70. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 09, 2019 Filed Dec 9, 2019 20:44 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 3,000 | $54.33 | $162,990.00 |
DisclosureSEC source: 0001209191-19-059779 · doc4.xml · nonDerivative · entry 7 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,069,219 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F7 · price: The weighted average sale price for the transaction reported was $54.33, and the range of prices were between $53.67 and $54.67. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 06, 2019 Filed Dec 9, 2019 20:44 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 14,263 | $51.02 | $727,698.26 |
DisclosureSEC source: 0001209191-19-059779 · doc4.xml · nonDerivative · entry 6 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,072,219 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F6 · price: The weighted average sale price for the transaction reported was $51.02, and the range of prices were between $50.905 and $51.33. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 06, 2019 Filed Dec 9, 2019 20:44 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 36,627 | $50.67 | $1,855,890.09 |
DisclosureSEC source: 0001209191-19-059779 · doc4.xml · nonDerivative · entry 5 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,086,482 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F5 · price: The weighted average sale price for the transaction reported was $50.67, and the range of prices were between $49.90 and $50.90. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 05, 2019 Filed Dec 9, 2019 20:44 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 22,630 | $52.84 | $1,195,769.20 |
DisclosureSEC source: 0001209191-19-059779 · doc4.xml · nonDerivative · entry 4 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,123,109 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F4 · price: The weighted average sale price for the transaction reported was $52.84, and the range of prices were between $52.495 and $53.48. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 05, 2019 Filed Dec 9, 2019 20:44 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 12,200 | $52.08 | $635,376.00 |
DisclosureSEC source: 0001209191-19-059779 · doc4.xml · nonDerivative · entry 3 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,145,739 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F3 · price: The weighted average sale price for the transaction reported was $52.08, and the range of prices were between $51.49 and $52.49. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 05, 2019 Filed Dec 9, 2019 20:44 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 21,280 | $50.93 | $1,083,790.40 |
DisclosureSEC source: 0001209191-19-059779 · doc4.xml · nonDerivative · entry 2 Cui Jingrong Jean · CIK 0001772259 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,157,939 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F2 · price: The weighted average sale price for the transaction reported was $50.93, and the range of prices were between $50.48 and $51.47. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 27, 2019 Filed Feb 26, 2020 20:18 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Exercise / conversionStock Option (right to buy) · Derivative | 54,220 | $0.00 Strike: $5.12 | $0.00 |
DisclosureSEC source: 0001209191-20-013266 · doc4.xml · derivative · entry 6 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 188,383 Underlying: Common Stock · 54,220 shares Expires 2028-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents options exercised by Yishan (Peter) Li, who is Jean Cui's spouse. F2 · derivative.exercise_date: The shares vest in 48 equal successive installments measured from the one month anniversary of September 29, 2018. Read SEC document |
| June 27, 2019 Filed Feb 26, 2020 20:18 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Exercise / conversionCommon Stock | 54,220 | $5.12 | $277,606.40 |
DisclosureSEC source: 0001209191-20-013266 · doc4.xml · nonDerivative · entry 2 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 835,439 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents options exercised by Yishan (Peter) Li, who is Jean Cui's spouse. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.